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Summary
 
Background
 
An essential criterion for control of acromegaly is
normalization of IGF-I levels. Somatostatin analogues act to
suppress IGF-I and GH levels.
 
Objective
 
To assess the efﬁcacy and safety of 48 weeks titrated
dosing of lanreotide Autogel.
 
Design
 
Open-label, multicentre, phase III, 48-week trial.
 
Methods
 
Patients with active acromegaly (IGF-I levels > 1·3 times
upper limit of age-adjusted normal range) were recruited. Twelve
injections of lanreotide Autogel were given at 28-day intervals:
during the 16-week ﬁxed-dose phase, patients received 90 mg; in the
32-week dose-titration phase, patients received 60, 90 or 120 mg
according to GH and IGF-I levels. Intention-to-treat analysis was
performed to determine the proportion of patients with normalized
age-adjusted IGF-I levels at study end. Secondary evaluations
included GH levels, clinical acromegaly signs and safety.
 
Results
 
Fifty-seven of 63 patients completed the study. Lanreotide
Autogel resulted in normalized age-adjusted IGF-I levels in 27
patients (43%, 95% CI 31–55). Mean GH levels decreased from 6·2
to 1·5 
 
μ
 
g/l at study end, with 53 of 62 patients (85%) having GH
levels 
 
≤
 
 2·5 
 
μ
 
g/l (95% CI 76·7–94·3) and 28 of 62 patients (45%) with
levels < 1 
 
μ
 
g/l (95% CI 32·8–57·6). Twenty-four (38%) had both
normal IGF-I levels and GH levels 
 
≤
 
 2·5 
 
μ
 
g/l. Acromegaly symptoms
reduced signiﬁcantly in most patients throughout the study. The
most common adverse events were gastrointestinal, as expected for
somatostatin analogues.
 
Conclusions
 
Using IGF-I as primary end-point, 48  weeks
lanreotide Autogel treatment, titrated for optimal hormonal control,
controlled IGF-I and GH levels effectively, reduced acromegaly
symptoms and was well tolerated.
(Received 2 October 2007; returned for revision 3 November 2007; 
 
ﬁnally revised 29 December 2007; accepted 5 January 2008)
 
Introduction
 
Acromegaly is a chronic disease characterized by increased circulating
levels of GH and IGF-I. Normalization of IGF-I levels is the main
objective for the control of acromegaly,
 
1
 
 and is associated with
improved cardiac function
 
2
 
 and reduction in excess mortality.
 
3,4
 
Suppression of GH and IGF-I can be achieved by treatment with
somatostatin analogues, which provide safe and effective management
of acromegaly.
 
5–7
 
 The somatostatin analogue lanreotide is available
as a long-acting aqueous gel formulation, lanreotide Autogel
(Beaufour Ipsen Pharma, Paris, France), which is administered
subcutaneously every 28 days from a ready-to-use preﬁlled syringe.
Previous studies have demonstrated the good efﬁcacy of lanreotide
Autogel in the management of patients with acromegaly.
 
8–12
 
Differing sensitivities to somatostatin analogues among patients
with acromegaly mean that the doses of lanreotide required to
normalize serum IGF-I levels will vary.
 
9
 
 Thus, individualizing dosing
relies on appropriate dose titration for optimal control of serum IGF-
I levels.
 
9
 
 The aim of this open-label study was to evaluate the efﬁcacy
of repeated injections of lanreotide Autogel for 48 weeks in a large
cohort of patients with acromegaly. To allow comparison with other
studies evaluating the effects of somatostatin analogues, as well as
those assessing GH antagonists,
 
13,14
 
 the percentage of patients with
a normal age-adjusted serum IGF-I level was chosen as the primary
outcome. Secondary efﬁcacy evaluations included the assessment of
GH levels and clinical acromegaly signs. The safety of treatment was
also documented.
 
Patients and methods
 
Patients
 
Patients (aged 
 
≥
 
 18 years) were recruited if they had active acromegaly,
deﬁned as IGF-I levels at least 1·3 times the upper limit of the
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age-adjusted normal range. Patients who had previously received
either a somatostatin analogue (other than lanreotide Autogel) or
a dopaminergic agonist could be included if this elevated level of
IGF-I was reached during the wash-out period, which lasted up to
12  weeks, depending on treatment previously administered. All
somatostatin analogue or dopaminergic agonist treatment had to be
discontinued at or before the ﬁrst screening visit. A second screening
visit was then scheduled as follows: 1 week after last administration
of short-acting formulations of octreotide or dopaminergic agonist;
4 weeks after last administration of lanreotide 30 mg or long-acting
dopaminergic agonist; and 8 weeks after last injection for long-
acting octreotide formulation. If necessary, a third screening visit was
scheduled 1 week after the previous visit for short-acting formula-
tions, and 4 weeks after the previous visit for all others. If enrolment
criteria were fulﬁlled at either of these visits, the patient was included.
Patients were excluded from the study if they had previously received
treatment with lanreotide Autogel. Patients were not permitted to
have undergone pituitary surgery within the previous 3 months or
have received radiotherapy for acromegaly within the previous
36 months.
All patients gave written, informed consent, and the study was
approved by the institutional ethics committee of each study centre.
The study was conducted in accordance with the Declaration of
Helsinki (South Africa, 1996).
 
Study design
 
This was an open-label, 48-week, phase III, multicentre study carried
out by 17 investigators (16 in France and 1 in Switzerland). The study
is registered on ClinicalTrials.gov (NCT00210457).
 
Interventions
 
Patients received a total of 12 injections of lanreotide Autogel at 28-
day intervals over two study phases: four injections in the ﬁxed-
dose phase and eight injections in the dose-titration phase.
During the ﬁxed-dose phase, all patients received 90 mg of lanreotide
Autogel, and in the dose-titration phase patients could receive 60,
90 or 120 mg. Dose adjustments occurred at weeks 16 and 32
according to patients GH and IGF-I levels as assessed at the preceding
visit (Fig.  1). The total duration of the treatment period was
48 weeks.
The dose was increased if GH levels were > 2·5 
 
μ
 
g/l or IGF-I levels
were above the upper limit of the age-adjusted normal range, and
decreased if GH levels were 
 
≤
 
 1 
 
μ
 
g/l and IGF-I levels were normal
or below normal. At each dose titration, the dose could only be
increased or decreased one level and, once increased to 120 mg, the
dose could not be decreased later.
 
Assessments and outcome measures
 
Blood samples were taken at 12, 28 and 48 weeks for evaluation
of GH and IGF-I levels, and haematology and biochemistry
measurements. GH and IGF-I levels were measured centrally.
Tumour volume was not measured.
A set of seven blood samples was gathered at 30-min intervals for
GH assessment at weeks 12 and 28, the last sample was taken just
prior to lanreotide Autogel injection. GH levels were measured
in a central laboratory using a GH immunoradiometric assay
(Immunotech 1397, Marseille, France) with a detection limit of
0·05 
 
μ
 
g/l. Maximal intra- and interassay coefﬁcients of variation
were 1·5% and 14%, respectively.
For assessment of IGF-I levels, a single blood sample was collected
at the same time as the ﬁrst GH sample. IGF-I levels were assayed
using a radioimmunoassay kit (Immunotech 3516). The detection
limit was 3 
 
μ
 
g/l and the intra- and interassay coefﬁcients of variation
were > 7·4% and 15·5%, respectively. The normal range was 219–
644 
 
μ
 
g/l for patients aged 18–30 years, 183–405 
 
μ
 
g/l for those aged
31–40 years, 54–336 
 
μ
 
g/l for patients aged 41–50 years, 71–284 
 
μ
 
g/l for
those aged 51–65 years and 45–259 
 
μ
 
g/l for patients aged 66–85 years.
In addition to the haematology and biochemical analyses, the
safety assessment was based on physical examination at each visit,
and gallbladder ultrasonography performed at baseline, and at weeks
28 and 48. Acromegaly symptoms were evaluated at each visit and
graded as absent (score = 0), mild (score = 1), moderate (score = 2)
or severe (score = 3).
The primary efﬁcacy end-point was the proportion of patients
with normal age-adjusted IGF-I levels at study end (week 48 of
treatment), deﬁned as a level at or below the upper limit of the
normal age-adjusted range.
Fig. 1 Study design schema. 
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Secondary objectives included documenting the variation in IGF-
I levels from baseline (expressed as a percentage of the upper limit
of the age-adjusted normal range); mean IGF-I and GH levels;
number of patients with serum GH levels of 
 
≤
 
 2·5 
 
μ
 
g/l or < 1 
 
μ
 
g/l;
and number of patients with no or reduced clinical signs of acromegaly.
 
Data analysis
 
The primary population for the assessment of efﬁcacy was the
intention-to-treat population, which comprised all patients who had
received at least one injection of lanreotide Autogel and had data for
at least one key efﬁcacy variable (i.e. data for GH or IGF-I levels at
any visit after week 0). The safety population included all patients
who received at least one injection of lanreotide Autogel. As this
was an open-label study, descriptive statistics were used. Efﬁcacy was
also assessed for subgroups of patients deﬁned by their baseline
characteristics.
 
Results
 
Patient disposition and baseline disease characteristics
 
Sixty-three patients were recruited into the study: all patients
completed the ﬁxed-dose phase, 59 completed the ﬁrst titrated-dose
phase and 57 completed the entire 48-week study. Six patients
withdrew prematurely: three because of adverse events, one due to
lack of efﬁcacy and two for other reasons (missing injections during
weeks 10–12 for one patient, and time interval was too long between
injections for the second patient).
Patients’ baseline characteristics are shown in Table 1. At the time
of inclusion, 46 patients (73%) had a macro-adenoma. With regard
to previous treatment for acromegaly, 37 patients (59%) had undergone
pituitary surgery, 12 (19%) had received pituitary radiotherapy and
49 (78%) had been medically treated.
 
Treatment
 
Following assessment of GH and IGF-I levels at week 12 (i.e. after
three injections of 90 mg), the dose of lanreotide Autogel given at
subsequent visits during the ﬁrst titrated-dose phase was decreased
to 60  mg in 11 patients, maintained at 90  mg in 4 patients and
increased to 120 mg in 44 patients. By the end of the study, lanreotide
Autogel was administered at the 60-mg dose in 9 patients (14%), at
the 90-mg dose in 4 patients (6%) and at the 120-mg dose in 46
patients (73%). The remaining four patients withdrew during the
ﬁxed-dose phase.
 
Efficacy
 
Primary efﬁcacy end-point. 
 
Treatment with lanreotide Autogel
resulted in normalized IGF-I levels (age-adjusted) in 27 patients
(43%, 95% CI 31–55) by the end of the study (Table 2).
Table 1. Baseline demographic and disease characteristics for the intention-
to-treat population
Characteristics n = 63
Mean (SD) age, years 55·3 (12·0)
Mean (SD) weight, kg 84·5 (18·8)
Mean (SD) time since diagnosis, years 7·8 (7·1)
Sex
n (%) male patients 38 (60)
n (%) female patients 25 (40)
Previous treatment*
n (%) patients who have had pituitary surgery 37 (59)
n (%) patients who have had pituitary radiotherapy 12 (19)
n (%) patients who have had pituitary medical treatment 49 (78)
Size of adenoma at diagnosis
n (%) patients with microadenoma 11 (17)
n (%) patients with macro-adenoma 46 (73)
n (%) patients with adenoma of unknown size 6 (10)
*Percentages add up to more than 100 because patients may have had 
more than one previous treatment.
Table 2. Patients with control of IGF-I levels or serum GH or both, for the intention-to-treat population
Baseline 
(n = 63)
Week 12 
(n = 61)
End of study 
(n = 63)
Age-adjusted IGF-I
Abnormal* Normal Abnormal Normal Abnormal
Patients, n (%)† 63 (100) 16 (26) 45 (74) 27 (43) 36 (57)
Dose of lanreotide Autogel (mg) – 90 90 60 90 120 60 90 120
Patients with both IGF-I and GH values, n‡ 6 3 1 6 4 5 951 2 033 4
GH level (μg/l)
< 1 7 11 8 8 3 6 0 1 10
1–2·5 15 3 25 1 1 5 0 1 18
> 2·5 41 2 12 0 1 1 0 1 6
*No results were normal at baseline.
†Last value available.
‡Last value available from last visit at which both IGF-I and GH values were obtained. 
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Secondary end-points. 
 
Serum IGF-I levels decreased throughout the
study period (Fig. 2a) and across all dose groups: during the study
mean (SE) IGF-I levels decreased from 432·3 (27·9) 
 
μ
 
g/l at week 12
to 376·9 (39·9) 
 
μ
 
g/l at the end of the study. After treatment completion,
mean IGF-I levels were 1·3 times the upper limit of the age-adjusted
normal range (range 0·3–4·0), compared with 2·5 times the upper
limit of the normal range at baseline (range 1·3–5·8).
When normalized IGF-I levels were analysed according to baseline
characteristics, there was no inﬂuence of gender or prior radiotherapy
on the proportion of patients responding.
Normalization of IGF-I levels was accompanied by a marked
decrease in mean (SE) GH levels, from 6·2 (1·1) 
 
μ
 
g/l at baseline to
1·5 (0·3) 
 
μ
 
g/l at study end (Fig. 2b). At the end of the study, more
patients in the 60- and 90-mg dose groups with normalized IGF-I
levels had GH levels < 1 
 
μ
 
g/l, compared with those who had
abnormal IGF-I levels (Table 2). After treatment, GH levels were
 
≤
 
 2·5 
 
μ
 
g/l in 53 of 62 patients (85%, 95% CI 77–94) and < 1 
 
μ
 
g/l in
28 of 62 patients (45%, 95% CI 33–58). One patient did not
have postbaseline GH data.
Twenty-four patients (38%) had both normal IGF-I levels and GH
levels of 
 
≤
 
 2·5 
 
μ
 
g/l, and 17 of 63 (27%) had both normal IGF-I levels
and a GH level of < 1 
 
μ
 
g/l. Only two patients had GH levels > 2·5 
 
μ
 
g/l.
Of the patients who maintained supranormal IGF-I levels, 30 of 37
(81%) achieved GH levels 
 
≤
 
 2·5 
 
μ
 
g/l.
Reductions in IGF-I and GH levels were associated with improve-
ments in acromegaly symptoms throughout the study (Fig.  3).
Asthenia was the most frequent acromegaly symptom at baseline. By
the end of the study, it had improved in 27 of 43 (63%) patients,
and was absent in 36 of 63 (57%) patients, compared with 19 of
62 (31%) at baseline. Similarly, joint pain improved in 27 of 35
(77%) patients who recorded this symptom at baseline. Swelling of
extremities, excessive perspiration and headache also improved at
the end of the study in 23 of 29 (79%), 21 of 26 (81%) and 15 of 22
(68%) patients, respectively.
 
Safety
 
The most common adverse events were gastrointestinal in nature,
with 36 (57%) and 17 (27%) patients reporting at least one episode
of diarrhoea or abdominal pain, respectively, over the 48-week study.
Liver and biliary system disorders occurred in 16 patients (25%),
with cholelithiasis reported in 10 (16%) and other gallbladder
disorders in 6 (10%). Ultrasonography, which was performed on
47 patients at baseline and at the end of the study, revealed that there
were eight new cases (17%) of gallstones and four new cases (9%)
Fig. 2 Reduction in mean (SE) levels of serum (a) IGF-I and (b) GH.
Fig. 3 Proportion of patients with acromegaly symptoms by visit over 
duration of study. 
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of gallbladder sludge at the end of the study. No cholecystitis or
cholangitis were observed.
Twenty-one patients (33%) at baseline and 25 (40%) at the end
of the study had fasting blood glucose values > 6·5 mmol/l. Adverse
events related to glycoregulation were reported in four patients: in
one patient diabetes control worsened, one developed diabetes
mellitus and two had hypoglycaemia.
The majority of adverse events were mild (111 events in 18
patients, 29%) or moderate (78 events in 25 patients, 40%) in
severity. Thirteen patients experienced serious adverse events
during the study, but only one was considered possibly related to the
study drug. This case of severe thrombophlebitis led to the early
withdrawal of the patient. Two other patients withdrew from the
study because of adverse events possibly or probably related to the
study drug (injection site pain in one and diarrhoea with abdominal
pain in the other).
 
Discussion
 
In this population of 63 patients with acromegaly who had been
treated with lanreotide Autogel, normalization of IGF-I levels was
demonstrated in 43% of patients who all had abnormal IGF-I levels
at study entry. This is comparable with a previous study in which
50% of patients given titrated doses of lanreotide Autogel achieved
IGF-I normalization.
 
9
 
 Although other studies cite slightly higher
percentages of patients achieving normalization in IGF-I levels,
 
15
 
 it
should be emphasized that, in contrast to other studies, this was the
primary end-point in our study and the data analysis was based on
the intention-to-treat population, recognized as the most realistic
unselected method of assessing the data. Additionally, strict entry
criteria were used to ensure that patients had active acromegaly –
that is, IGF-I levels increased at least 1·3 times the upper limit of the
age-adjusted normal range. In contrast, in the other studies patients
were selected on the basis of either GH level or marginally increased
levels of IGF-I only.
 
15
 
 This may be of importance when interpreting
the results, as the response is generally better when baseline GH levels
are not highly elevated.
 
15
 
 Furthermore, although the inclusion
criteria for this study were based on IGF-I levels only, all except one
patient met the Cortina consensus criteria for active acromegaly
(random GH > 0·4 
 
μ
 
g/l and IGF-I levels above the age- and
sex-adjusted normal range).
 
16
 
 The proportion of patients achieving
normalized IGF-I levels in this study was not inﬂuenced by gender
or prior radiotherapy.
In this study, GH levels 
 
≤
 
 2·5 
 
μ
 
g/l were achieved in 85% of
patients, higher than the percentage reported (68%) for titrated-dose
lanreotide Autogel.
 
9
 
 GH levels < 1 
 
μ
 
g/l were achieved in 45% of
patients, a higher proportion than achieved with octreotide
treatment in a previous study (27%).
 
17
 
This study was conducted in accordance with recent guidelines,
which recommend assessing GH and IGF-I control using clearly
deﬁned ranges that were updated following recent advances in
biochemical assay technologies.
 
1
 
 The criteria for biochemical control
of acromegaly that will best reduce disease-related morbidity are
debated, and there remains no consensus regarding the criteria that
predict a response to treatment. GH levels continue to have relevance
as a disease marker, and may be the best predictors of the subtle GH
excess or early GH dysregulation that is a precursor to acromegaly
recurrence in some patients.
 
18
 
 Several studies have shown that
achieving normal IGF-I levels is a good prognostic factor for acromegaly
in terms of morbidity,
 
19–21
 
 but also for mortality.
 
3,22
 
 Other studies,
however, do not support the link between IGF-I level and excess
mortality.
 
23,24
 
 One recent study supports the validity of the currently
used biochemical criteria for assessing long-term mortality and
morbidity, but suggests that they may be insufﬁcient in addressing
patient quality of life.
 
25
 
 Therefore, the association between the
improved hormonal control, in terms of both IGF-I and GH level,
and the decrease in incidence of acromegaly symptoms in this study
reinforces the concept of IGF-I as a useful disease marker.
Discordant results in the achievement of both GH levels 
 
≤
 
 2·5 
 
μ
 
g/l
and normal IGF-I levels are frequently observed when treating
acromegaly patients with somatostatin analogues,
 
17,26
 
 and also after
surgery.
 
27
 
 Similarly, in our study there were 30 patients with GH
levels 
 
≤
 
 2·5 
 
μ
 
g/l but high IGF-I levels, and two patients with normal
IGF-I levels but high GH levels. Reasons for why such discordance
might occur in some patients have been proposed.
 
17
 
 There is general
agreement that achieving GH levels 
 
≤
 
 2·5 
 
μ
 
g/l is not sufﬁcient for the
disease to be considered controlled;
 
28
 
 it is thought that the persistence
of a continuous, albeit low, hypersecretion of GH (which can be
detected with very sensitive assays) may promote the increased IGF-
I levels seen in some patients.
 
28
 
 The situation whereby patients have
normal IGF-I levels but high GH levels occurs less frequently.
 
29
 
It may be related to the fact that IGF-I levels are not only dependent
on GH levels, but also on other factors which may interfere with
sensitivity to GH at the receptor or the postreceptor level (e.g. the
levels of oestrogens, the general nutritional state or the presence of
diabetes).
 
29,30
 
 A direct peripheral effect of somatostatin analogues at
a hepatic level has also been suggested to control the GH–IGF-I axis,
and may provide an explanation for the discordant GH and IGF-I
suppression found in some patients receiving these drugs.
 
31
 
In this study, following a starting dose of 90 mg of lanreotide
Autogel, doses were titrated up to 120 mg or down to 60 mg according
to GH and IGF-I levels, and therefore hormonal responsiveness. In
our experience, although the initial dose of lanreotide Autogel does
not appear to affect the rates of hormonal response achieved at
optimal control after dose titration, initiation of treatment at 90 mg
may result in lower annual cumulative GH concentrations. Thus, the
90-mg dose represents the optimal starting dose. Notably, Ashwell
 
et al
 
.
 
10
 
 also used 90 mg as a starting dose – patients were switched
from long-acting octreotide to 90-mg lanreotide Autogel, with the
ﬁnding that acromegaly was at least as well controlled by lanreotide
Autogel as it had been previously.
Fewer patients receiving the 60-mg dose had abnormal GH and/or
IGF-I levels compared with those receiving higher doses, indicating
that the patients whose doses are titrated down are the best responders
and therefore able to achieve good control with a low dose. This
improved efﬁcacy at lower doses has been demonstrated,
 
8
 
 and
suggests that patients vary in their sensitivity to lanreotide Autogel.
Like somatostatin, somatostatin analogues bind to receptors (sst)
present on the cell surface of target organs. Five subtypes (sst1–5)
have been described, and the currently available somatostatin
analogues bind with high afﬁnity to sst2 and sst5. Partial or total
resistance of GH-secreting adenomas to somatostatin analogues is 
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in part due to variable tumoural expression or reduced receptor
density of the ﬁve known sst subtypes.
 
32
 
The majority of patients had their doses titrated up, but 14%
responded sufﬁciently to be able to have their dose titrated down to
the lowest dose. The dose-titration frequency (12-week intervals)
employed in this study is used widely in clinical practice – generally
the dose of lanreotide Autogel is increased when the GH level is
> 2·5 
 
μ
 
g/l or the IGF-I level is outside of the age-adjusted normal
range. The results are consistent with year-long dose-titration studies
of other somatostatin analogues.
9,30 An alternative to changing the dose
is to change the frequency of dosing;
33,34 for example, it has recently
been reported that patients whose acromegaly is well-controlled with
lanreotide Autogel 120 mg every 4 weeks may be able to have their
dose interval extended to every 6–8 weeks without loss of efﬁcacy.
35,36
The general safety of repeated injections of lanreotide Autogel was
assessed using standard haematology and biochemistry tests,
physical examination and adverse event reporting. Treatment was
well tolerated in this 48-week study and, as expected with somato-
statin analogues, the adverse effects were predominantly minor,
involving transient gastrointestinal problems, such as diarrhoea and
abdominal pain. There is an increased tendency for gallstone
formation during long-term somatostatin analogue treatment, but
gallbladder echocardiography performed at the end of this study
revealed only a slight increase in the presence of gallstones or sludge
(eight and four new cases, respectively). There were no cases of
complicated gallstones. As a result of their inhibition of the secretion
of insulin and glucagon, treatment with somatostatin analogues may
be associated with disturbance of glucose control. In the present
study, the proportion of patients with clinically signiﬁcant abnormal
glucose values was slightly higher at the end of the study (40%)
compared with at baseline (33%), although adverse events of
glycoregulation were mixed (two cases of new or aggravated diabetes
mellitus and two cases of hypoglycaemia). It is recommended that
blood glucose levels are monitored when lanreotide treatment is
started, or when the dose is altered and any antidiabetic treatment
adjusted accordingly.
Conclusion
By the end of this 48-week study of lanreotide Autogel, in which IGF-
I was used as the primary efﬁcacy criterion, 43% of patients with
acromegaly had normalized age-adjusted levels. This was accompanied
by control of GH to levels ≤ 2·5 μg/l in 85% of patients and reduction
in acromegaly symptoms. Lanreotide Autogel was well tolerated with
the safety proﬁle expected of a somatostatin analogue.
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